Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
'Dancing With the Stars' Season 34 finale: Who might win the mirror ball trophy? Where do the remaining contestants rank? - 2Innospace's rocket crashes in first commercial launch in Brazil; shares tumble
- 3Major railway disruptions persist as Germany braces for more snow
- 4Finding the Universe of Craftsmanship: Individual Encounters in Imagination
- 5Don't miss these five impressive spots in Bangkok
- New trailer for 'Bridgerton' Season 4 teases Benedict's love story: Watch it here
- 'War is not over': Detailed diagrams of prisons found in cells of Oct. 7 terrorists
- 4 Creative Savvy Home Gadgets of 2024: Reforming Home Robotization and Security
- Merz: 80% of Syrians in Germany should return in three years
- IDF strikes Hamas terror cell operating near Israeli troops in northern Gaza
- Allow Innovative Progressions To have a Tremendous Effect
- From Exemplary to Current: Famous Rings Available
- Merz says army could be involved in mine-clearing from Hormuz
- Guns N' Roses 2026 Tour: How to get tickets, presale times, prices and more
